Form 4: Tandem Diabetes COO Executes RSU Vesting Transaction

Jean-Claude Kyrillos, EVP and COO of Tandem Diabetes Care, reported the vesting of 3,636 restricted stock units and the withholding of 1,926 shares for tax obligations.

Summary

• Jean-Claude Kyrillos, EVP & Chief Operating Officer of Tandem Diabetes Care, Inc. (TNDM), completed a transaction involving the vesting of 3,636 restricted stock units (RSUs) on April 15, 2026.
• The company withheld 1,926 shares to satisfy mandatory tax withholding requirements associated with the RSU vesting.
• Following these transactions, the reporting person holds 25,772 shares of common stock directly.
• The remaining unvested RSU balance for the reporting person is 18,181 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive equity compensation with no impact on company operations or financial strategy.

Positives

• The transaction reflects the standard vesting of equity compensation, indicating ongoing alignment between executive incentives and company performance.

Negatives

• None identified; this is a routine administrative transaction related to tax withholding on equity awards.

Risks

• None identified; this is a standard regulatory disclosure of executive equity movement.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of executive equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related share withholding are standard practices for executive compensation in the medical device sector, reflecting typical corporate governance and tax compliance procedures.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive equity compensation.
• The use of 'sell-to-cover' or share withholding for tax obligations is a common industry practice among publicly traded companies to manage tax liabilities for employees.

Stakeholder Impact

• No material impact on shareholders, employees, or creditors as this is a standard equity compensation event.

Next Steps

• Continued vesting of remaining 18,181 RSUs in quarterly installments as per the 2023 Long-Term Incentive Plan.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Executive Compensation